Demographics and disease characteristics of patients included in the analysis (N = 323)
| . | Number (%) . | ||
|---|---|---|---|
| All patients . | Firstline . | Secondline or greater . | |
| Total | 323 | 194 (60) | 129 (40) |
| Age, median, y (range) | 65 (20-92) | 66 (20-88) | 62 (31-92) |
| Sex | |||
| Male | 161 (50) | 93 (48) | 68 (53) |
| Female | 160 (50) | 101 (52) | 59 (46) |
| Missing data | 2 (0.7) | 0 | 2 (2) |
| ACE-27 score | |||
| 0 (none) | 150 (46) | 81 (42) | 69 (53) |
| 1 (mild) | 86 (26) | 60 (31) | 26 (20) |
| 2 (moderate) | 54 (17) | 34 (18) | 20 (16) |
| 3 (severe) | 32 (10) | 19 (10) | 13 (10) |
| Missing data | 1 (<1) | 0 | 1 (<1) |
| Histological subtype | |||
| FL | 175 (54) | 111 (57) | 64 (50) |
| LPL | 54 (17) | 32 (16) | 22 (17) |
| MCL | 34 (11) | 19 (10) | 15 (12) |
| MZL | 33 (10) | 22 (11) | 11 (9) |
| Extranodal marginal zone (MALT) | 11 (3) | 5 (3) | 6 (5) |
| Splenic marginal zone lymphoma | 11 (3) | 3 (2) | 8 (6) |
| Other indolent B-NHL | 5 (2) | 2 (1) | 3 (2) |
| Ann Arbor stage at diagnosis | |||
| I | 10 (3) | 6 (3) | 4 (3) |
| II | 27 (8) | 20 (10) | 7 (5) |
| III | 53 (16) | 36 (19) | 17 (13) |
| IV | 217 (67) | 127 (65) | 90 (70) |
| NA | 16 (5) | 5 (3) | 11 (9) |
| B symptoms | |||
| Yes | 79 (24) | 44 (23) | 35 (27) |
| No | 210 (65) | 128 (66) | 82 (64) |
| Not known | 34 (11) | 22 (11) | 12 (9) |
| Extranodal disease | |||
| Yes | 142 (44) | 81 (42) | 61 (47) |
| No | 155 (48) | 93 (48) | 62 (48) |
| Not known | 26 (8) | 20 (10) | 6 (5) |
| Bone marrow involvement∗ | |||
| Yes | 176 (54) | 99 (51) | 77 (60) |
| No | 102 (32) | 68 (35) | 34 (26) |
| Not known | 45 (14) | 27 (14) | 18 (14) |
| Bulky disease† | |||
| Yes | 61 (19) | 41 (21) | 20 (16) |
| No | 224 (69) | 128 (66) | 96 (74) |
| Not known | 38 (12) | 25 (13) | 13 (10) |
| FLIPI score (in 175 patients with FL)‡ | |||
| Low | 31 (18) | 22 (20) | 9 (14) |
| Moderate | 50 (29) | 40 (36) | 10 (16) |
| High | 72 (41) | 41 (37) | 31 (8) |
| Missing | 22 (13) | 8 (6) | 14 (22) |
| sMIPI score in 34 patients with MCL§ | |||
| Low | 5 (15) | 3 (16) | 2 (13) |
| Intermediate | 13 (38) | 7 (37) | 6 (40) |
| High | 15 (44) | 8 (42) | 7 (47) |
| Missing/inapplicable | 1 (3) | 1 (5) | 0 |
| Performance status at start of induction n = 323 (n, %) | |||
| 0 | 123 (38) | 87 (45) | 36 (28) |
| 1 | 151 (47) | 82 (42) | 69 (53) |
| 2 | 30 (9) | 11 (6) | 19 (15) |
| 3 | 10 (3) | 6 (3) | 4 (3) |
| 4 | 1 (<1) | 0 () | 1 (<1) |
| Missing data | 8 (2) | 8 (4) | 0 |
| Performance status at start of maintenance, n = 147 (n, %) | |||
| 0 | 66 (45) | 53 (45) | 13 (43) |
| 1 | 63 (43) | 48 (41) | 15 (50) |
| 2 | 9 (6) | 7 (6) | 2 (7) |
| Missing/inapplicable | 9 (6) | 9 (8) | 0 |
| Baseline lymphopenia | |||
| At start of induction | 89 of 295 (30) | 45 (26) | 44 (36) |
| At start of maintenance | 103 of 132 (78) | 79 (77) | 24 (80) |
| Follow-up time from commencement of bendamustine; median (range) | 34 mo (0-62) | 36.3 | 32.3 |
| Prior treatments in 129 patients | |||
| Median number of prior treatments | 2 | ||
| R-CHOP/R-CVP | 83 (64) | ||
| Rituximab monotherapy | 24 (19) | ||
| Fludarabine based | 19 (15) | ||
| HD chemotherapy/transplantation | 14 (11) | ||
| Radiotherapy | 9 (7) | ||
| Platinum based | 4 (3) | ||
| Splenectomy | 4 (3) | ||
| Ibrutinib | 2 (2) | ||
| . | Number (%) . | ||
|---|---|---|---|
| All patients . | Firstline . | Secondline or greater . | |
| Total | 323 | 194 (60) | 129 (40) |
| Age, median, y (range) | 65 (20-92) | 66 (20-88) | 62 (31-92) |
| Sex | |||
| Male | 161 (50) | 93 (48) | 68 (53) |
| Female | 160 (50) | 101 (52) | 59 (46) |
| Missing data | 2 (0.7) | 0 | 2 (2) |
| ACE-27 score | |||
| 0 (none) | 150 (46) | 81 (42) | 69 (53) |
| 1 (mild) | 86 (26) | 60 (31) | 26 (20) |
| 2 (moderate) | 54 (17) | 34 (18) | 20 (16) |
| 3 (severe) | 32 (10) | 19 (10) | 13 (10) |
| Missing data | 1 (<1) | 0 | 1 (<1) |
| Histological subtype | |||
| FL | 175 (54) | 111 (57) | 64 (50) |
| LPL | 54 (17) | 32 (16) | 22 (17) |
| MCL | 34 (11) | 19 (10) | 15 (12) |
| MZL | 33 (10) | 22 (11) | 11 (9) |
| Extranodal marginal zone (MALT) | 11 (3) | 5 (3) | 6 (5) |
| Splenic marginal zone lymphoma | 11 (3) | 3 (2) | 8 (6) |
| Other indolent B-NHL | 5 (2) | 2 (1) | 3 (2) |
| Ann Arbor stage at diagnosis | |||
| I | 10 (3) | 6 (3) | 4 (3) |
| II | 27 (8) | 20 (10) | 7 (5) |
| III | 53 (16) | 36 (19) | 17 (13) |
| IV | 217 (67) | 127 (65) | 90 (70) |
| NA | 16 (5) | 5 (3) | 11 (9) |
| B symptoms | |||
| Yes | 79 (24) | 44 (23) | 35 (27) |
| No | 210 (65) | 128 (66) | 82 (64) |
| Not known | 34 (11) | 22 (11) | 12 (9) |
| Extranodal disease | |||
| Yes | 142 (44) | 81 (42) | 61 (47) |
| No | 155 (48) | 93 (48) | 62 (48) |
| Not known | 26 (8) | 20 (10) | 6 (5) |
| Bone marrow involvement∗ | |||
| Yes | 176 (54) | 99 (51) | 77 (60) |
| No | 102 (32) | 68 (35) | 34 (26) |
| Not known | 45 (14) | 27 (14) | 18 (14) |
| Bulky disease† | |||
| Yes | 61 (19) | 41 (21) | 20 (16) |
| No | 224 (69) | 128 (66) | 96 (74) |
| Not known | 38 (12) | 25 (13) | 13 (10) |
| FLIPI score (in 175 patients with FL)‡ | |||
| Low | 31 (18) | 22 (20) | 9 (14) |
| Moderate | 50 (29) | 40 (36) | 10 (16) |
| High | 72 (41) | 41 (37) | 31 (8) |
| Missing | 22 (13) | 8 (6) | 14 (22) |
| sMIPI score in 34 patients with MCL§ | |||
| Low | 5 (15) | 3 (16) | 2 (13) |
| Intermediate | 13 (38) | 7 (37) | 6 (40) |
| High | 15 (44) | 8 (42) | 7 (47) |
| Missing/inapplicable | 1 (3) | 1 (5) | 0 |
| Performance status at start of induction n = 323 (n, %) | |||
| 0 | 123 (38) | 87 (45) | 36 (28) |
| 1 | 151 (47) | 82 (42) | 69 (53) |
| 2 | 30 (9) | 11 (6) | 19 (15) |
| 3 | 10 (3) | 6 (3) | 4 (3) |
| 4 | 1 (<1) | 0 () | 1 (<1) |
| Missing data | 8 (2) | 8 (4) | 0 |
| Performance status at start of maintenance, n = 147 (n, %) | |||
| 0 | 66 (45) | 53 (45) | 13 (43) |
| 1 | 63 (43) | 48 (41) | 15 (50) |
| 2 | 9 (6) | 7 (6) | 2 (7) |
| Missing/inapplicable | 9 (6) | 9 (8) | 0 |
| Baseline lymphopenia | |||
| At start of induction | 89 of 295 (30) | 45 (26) | 44 (36) |
| At start of maintenance | 103 of 132 (78) | 79 (77) | 24 (80) |
| Follow-up time from commencement of bendamustine; median (range) | 34 mo (0-62) | 36.3 | 32.3 |
| Prior treatments in 129 patients | |||
| Median number of prior treatments | 2 | ||
| R-CHOP/R-CVP | 83 (64) | ||
| Rituximab monotherapy | 24 (19) | ||
| Fludarabine based | 19 (15) | ||
| HD chemotherapy/transplantation | 14 (11) | ||
| Radiotherapy | 9 (7) | ||
| Platinum based | 4 (3) | ||
| Splenectomy | 4 (3) | ||
| Ibrutinib | 2 (2) | ||
FLIPI, Follicular Lymphoma International Prognostic Index; MALT, mucosa associated lymphoid tissue; NA, not available; sMIPI, simplified Mantle Cell Lymphoma International Prognostic Index.
Patients with bone marrow involvement are classified as having extranodal disease.
Bulky disease is defined as tumor that is ≥7 cm in greatest dimension.
Based on number of risk factors: 0 or 1 risk factor indicates low risk, 2 risk factors indicate moderate risk, and >2 indicates high risk.
sMIPI is based on calculation of risk factors: low risk (score, 0-3); intermediate, (score, 4-5), or high risk (score, 6-11).